ROS-Responsive Fluorinated Oxalate Nanomedicine for Dual Chemiluminescence/1⁹F MRI Imaging and Targeted Drug Release
Authors:
- Anatoly PeshkovAPAnatoly Peshkov
- Anel UrazaliyevaAUAnel Urazaliyeva
- Dariyana SaiduldinovaDSDariyana Saiduldinova
- Kazbek KulbergenovKKKazbek Kulbergenov
- Nasir Bala AlhassanNANasir Bala Alhassan
- Almaz BeisenbayevABAlmaz Beisenbayev
- Yerkin ShabdanYSYerkin Shabdan
- Bauyrzhan UmbayevBUBauyrzhan Umbayev
- Vsevolod PeshkovVPVsevolod Peshkov
- Timur Sh. AtabaevTimur Sh. Atabaev
- Timur ElebessovTETimur Elebessov
- Tri Thanh PhamTPTri Thanh Pham
Open Access
- 2 April 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3304
Abstract
In this study, we developed a novel theranostic nanomedicine formulation that integrates multimodal imaging with controlled drug release in reactive oxygen species (ROS)-rich microenvironments. A fluorinated oxalate compound (FOC) was synthesized through a one-step condensation reaction between 1,1,1,3,3,3-hexafluoro-2-propanol and oxalyl chloride, characterized by 1H, 13C, and 1⁹F NMR spectroscopy. The FOC and luminophore-incorporated nanomedicine formulations reacted rapidly with hydrogen peroxide via the peroxyoxalate chemiluminescence (POCL) mechanism, producing strong chemiluminescence and inducing a notable 19-fold increase in ratiometric 1⁹F NMR signal upon conversion to fluorinated alcohol (FAH), demonstrating promising potential for high-contrast 1⁹F MRI in deep tissue. Following ROS stimulation, the chemical conversion from hydrophobic FOC to hydrophilic FAH led to the degradation of the nanomedicines, facilitating payload release. In vitro experiments with A-431 cancer cells under hypoxic conditions confirmed ROS-responsive drug release, evidenced by enhanced fluorescence from model luminophores. Additionally, doxorubicin-loaded FOC nanomedicines reduced cell viability to 32% under hypoxia while remaining non-toxic in normoxic conditions. These results indicate that FOC-based nanomedicine formulations provide a promising platform for combined chemiluminescence and 1⁹F MRI with targeted therapeutic efficacy in ROS-rich inflammatory and cancerous tissues.Keywords
Funding Information
- Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan (AP19679202, 11022021CRP1501)
- Nazarbayev University (AP19679202, 11022021CRP1501)
This publication has 27 references indexed in Scilit:
- Enhancing Molecular‐Level Biological Monitoring with a Smart Self‐Assembling 19F‐Labeled ProbeAngewandte Chemie International Edition, 2024
- Revisiting reactive oxygen species production in hypoxiaPflügers Archiv - European Journal of Physiology, 2024
- In Vivo Nitroreductase Imaging via Fluorescence and Chemical Shift Dependent 19F NMRAngewandte Chemie International Edition, 2022
- Ratiometric pH-Responsive 19F Magnetic Resonance Imaging Contrast Agents Based on Hydrazone SwitchesAnalytical Chemistry, 2022
- Reaction-Based Fluorescent Probes for the Detection and Imaging of Reactive Oxygen, Nitrogen, and Sulfur SpeciesAccounts of Chemical Research, 2019
- Rational design for enhancing inflammation-responsive in vivo chemiluminescence via nanophotonic energy relay to near-infrared AIE-active conjugated polymerBiomaterials, 2016
- Control of polymeric nanoparticle size to improve therapeutic deliveryJournal of Controlled Release, 2015
- Chemiluminescence‐Generating Nanoreactor Formulation for Near‐Infrared Imaging of Hydrogen Peroxide and Glucose Level in vivoAdvanced Functional Materials, 2010
- FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative StressCell, 2007
- Fluorescence probes used for detection of reactive oxygen speciesJournal of Biochemical and Biophysical Methods, 2005